Uses of Isotera Injection Concentrate 20mg/ml

Isotera Injection Concentrate 20mg/ml contains the active ingredient Docetaxel, which is indicated in the treatment of breast cancer, prostate cancer, lung cancer, ovarian cancer and head and neck cancer... Use and note when using Isotera through the article below.

Isotera is prepared in the form of a solution for injection. Each vial of 1ml of solution for injection contains 21.34mg of Doceraxel, a clear viscous solution for injection, pale yellow to slightly yellowish brown in color.
Isotera Injection is indicated in the following diseases:
Breast cancer: Isotera is used alone or in combination with other drugs in the treatment of breast cancer; Non-small cell lung cancer: Isotera is indicated alone in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. In addition, Isotera in combination with Cisplatin for the treatment of non-resectable locally advanced or metastatic non-small cell lung cancer; Prostate cancer: Docetaxel in combination with Prednisolone or Prednisone in the treatment of hormone-resistant metastatic prostate cancer; Gastric adenocarcinoma: Docetaxel in combination with 5-fluororacil and Cisplatin in the treatment of metastatic gastric adenocarcinoma; Head and neck cancer: Docetaxel in combination with 5-Fluororacil and Cisplatin in the treatment of locally advanced head and neck squamous cell carcinoma.

Dosage of Isotera should be limited by a unit that specializes in the use of cytotoxic chemotherapy and should be supervised by a physician with expertise in the use of anticancer chemotherapy.
The recommended dose of Isotera is as follows:
For breast cancer, stomach cancer, non-small cell lung cancer, and head and neck cancer: Pre-administer 1 oral corticosteroid (Dexamethasone 16mg/day) for 3 days before treatment with Docetaxel 1 day. Prophylactic granulocyte colony-stimulating factor may be used to reduce the risk of hematologic toxicity. The recommended dose of Docetaxel is 75-100mg/m2 infused over 1 hour; The recommended dose of Isotera is a 1-hour infusion every 3 weeks.

Isotera medicine can cause some unwanted effects as follows:
Immune system disorders: Usually occurs after a few minutes of infusion with symptoms of itchy or non-itchy rash, skin redness, back pain, chest, fever chills, difficulty breathing... More severe reactions characterized by generalized erythema, bronchospasm; Nervous system disorders: dysesthesia, paresthesia; Skin and soft tissue disorders: Rash localized mainly on hands, feet, face and chest including pruritus; peeling skin; Systemic or infusion site disorders: Inflammation, skin hyperpigmentation at the injection site, skin redness, dry skin, vein swelling, phlebitis or extravasation, peripheral edema; Digestive disorders: Diarrhea, stomatitis, vomiting, nausea, constipation, abdominal pain, gastric bleeding and esophagitis; Musculoskeletal system disorders: Myalgia; Infections, parasitic infections: Pneumonia, infections associated with agranulocytosis.

4.1. Contraindications Contraindicated to use Isotera drug in the following cases:
Patients with hypersensitivity to any ingredient of Isotera drug; Patients with neutrophil count less than 1,500 cells/mm3; Patients with severe liver failure; 4.2. Agranulocytosis is the most common adverse reaction during treatment with Docetaxel, so patients should closely monitor their WBC counts during treatment. In the case of severe neutropenia during a course of Isotera therapy, it is recommended that the dose be reduced in the next course or appropriate symptomatic treatment is used. Patients should be monitored for hypersensitivity reactions, especially during the first and second infusions. Hypersensitivity reactions may occur within a few minutes of dosing, so appropriate precautions should be taken. Localized erythema of the extremities associated with edema has been reported. In addition, patients with severe fluid retention such as pericardial effusion or pleural effusion should be closely monitored. Monitor liver function and conduct liver function tests periodically during treatment with Docetaxel. Use in Pregnancy: Animal studies have shown that Docetaxel is toxic to both the fetus and the fetus, reducing fertility in rats. Therefore, the use of Isotera is contraindicated in pregnant women, women in the reproductive period need to use appropriate contraception during treatment with Isotera Injection. For lactating women: There are no studies demonstrating the ability of Docetaxel to be excreted in human milk, so Isotera is contraindicated in lactating women.

Concomitant use of Isotera with cytochrome P450-3A inhibitors or inducers such as Terfenadin, Cyclosporin, Erythromycin, Ketoconazole, Troleandomycin...
Caution should be taken when using Docetaxel concomitantly with strong CYP3A4 inhibitors such as Ketoconazole , Ritonavir, Itraconazole... Scientific studies have shown that the clearance of Docetaxel is halved when co-administered with Ketoconazole. The dose of Isotera may have to be reduced by 50% in case of combined use of the above drugs.
Above is all information about Isotera, patients need to carefully read the instructions for use, consult a doctor / pharmacist before using. Absolutely do not arbitrarily buy Isotera treatment at home because there may be unwanted side effects.